Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment

Overview of attention for article published in Melanoma Research, April 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,656 followers.

RT @rutkowskip1972: Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma… ht…

05 Apr 2023

Reply Repost Favourite

RT @rutkowskip1972: Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma… ht…

05 Apr 2023

Reply Repost Favourite

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma… https://t.co/lLAyODRepL next important study from Polish Melanoma Group congrats for Cybulska-Stopa et al. @NIO_PIB @OnkologiaPolska

05 Apr 2023

Reply Repost Favourite

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment https://t.co/CrSIFKoW99 https://t.co/cSq3G6uxXj

05 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.